Jason K Perry

13PUBLICATIONS
77CO-AUTHORS
Nephrology and urologyMedical molecular engineering of nucleic acids and proteinsCondensed matter characterisation technique developmentGene and molecular therapyProteins and peptides
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 10, 2026
Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired and immunocompromised patients with COVID-19.

|Jan 07, 2026
Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects.

Nina Pennetzdorfer, Vidula Naik, Sally Demirdjian

|Oct 08, 2025
A structural roadmap for the formation of the coronavirus nsp3/nsp4 double membrane vesicle pore and its implications for polyprotein processing and replication/transcription.

Jason K Perry, Samuel Itskanov, John P Bilello

|Oct 01, 2025
Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure Prophylaxis.

Eda Canales, Winston Tse, Scott D Schroeder

|Jul 17, 2024
Discovery of GS-7682, a Novel 4'-Cyano-Modified C-Nucleoside Prodrug with Broad Activity against Pneumo- and Picornaviruses and Efficacy in RSV-Infected African Green Monkeys.

Dustin S Siegel, Hon C Hui, Jared Pitts

|May 22, 2024
The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses.

David R Martinez, Fernando R Moreira, Nicholas J Catanzaro

Pageof 3

Frequent Collaborators

3 joint publications

John P Bilello

3 joint publications

Joy Y Feng

2 joint publications

Egor P Tchesnokov

2 joint publications

Timothy P Sheahan